comparemela.com
  1. Home
  2. Live Updates
  3. American Cancer Society Inc - Breaking News

Latest Breaking News On - American cancer society inc - Page 9 : comparemela.com

NACD LAUNCHES COMMISSION TO EXPLORE THE FUTURE OF THE AMERICAN BOARDROOM

/PRNewswire/ The National Association of Corporate Directors (NACD), the authority on boardroom practices representing more than 23,000 board members, today.

New yorkUnited statesLarry thompsonFreddie macSidley austinOrlando ashfordPearl meyerJudy samuelsonSusan oliverShelley leibowitzNora denzelJohn roeJan babiakLuis aguilarSara mathewTeresa sebastian

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

/PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the.

United statesJon pattonDirk arnoldTimothy mccarthyOncolytics biotech incCompany contactAmerican cancer society incGerman cancer societyOncolytics biotechSecurities exchangeAmerican cancer societyAsklepios tumorzentrum hamburgColorectal cancerPancreatic cancerAnal cancerSecurities exchange act

NACD LAUNCHES COMMISSION TO EXPLORE THE FUTURE OF THE AMERICAN BOARDROOM

/PRNewswire/ The National Association of Corporate Directors (NACD), the authority on boardroom practices representing more than 23,000 board members, today.

New yorkUnited statesLarry thompsonFreddie macSidley austinOrlando ashfordPearl meyerJudy samuelsonSusan oliverShelley leibowitzNora denzelJohn roeJan babiakLuis aguilarSara mathewTeresa sebastian

Oncolytics Biotech Inc : Oncolytics Biotech Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review Multi-center

United statesJon pattonDirk arnoldTimothy mccarthyOncolytics biotech incGerman cancer societyCompany contactSecurities exchangeAmerican cancer society incAmerican cancer societyAsklepios tumorzentrum hamburgColorectal cancerPancreatic cancerAnal cancerSecurities exchange act

Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

/PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the.

United statesJon pattonDirk arnoldTimothy mccarthyOncolytics biotech incCompany contactAmerican cancer society incGerman cancer societyOncolytics biotechSecurities exchangeAmerican cancer societyAsklepios tumorzentrum hamburgColorectal cancerPancreatic cancerAnal cancerSecurities exchange act

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.